BioForce Nanosciences Holdings, Inc. reported zero revenues and a critically low current ratio of 0.01 as of Q1 2026, reinforcing its precarious liquidity position. Its business model centers on natural vitamins and nutritional supplements aimed at promoting active lifestyles but lacks any recent sales traction or product market penetration. Operating losses and accumulated deficits exceed $162 million, with survival hinging on obtaining new capital amid a highly fragmented and competitive nutritional supplements sector. Key operational risks stem from insufficient working capital, going concern qualifications, and execution uncertainties tied to fundraising success.